Crossmark Global Holdings Inc. Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Crossmark Global Holdings Inc. increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 17.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,362 shares of the medical research company’s stock after buying an additional 2,182 shares during the period. Crossmark Global Holdings Inc.’s holdings in IQVIA were worth $2,822,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Simplify Asset Management Inc. raised its position in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Versor Investments LP purchased a new stake in shares of IQVIA in the third quarter valued at $1,328,000. JPMorgan Chase & Co. increased its position in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Finally, CIBC Asset Management Inc raised its stake in IQVIA by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock valued at $62,501,000 after purchasing an additional 8,490 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the subject of a number of recent research reports. Morgan Stanley lowered their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. TD Cowen reduced their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Evercore ISI decreased their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Stock Performance

NYSE:IQV opened at $205.37 on Thursday. The firm has a 50-day moving average of $199.53 and a two-hundred day moving average of $221.30. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a market cap of $37.27 billion, a P/E ratio of 26.95, a PEG ratio of 2.01 and a beta of 1.48. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.